AAN 2016 Multiple Sclerosis

Further Immunomodulatory Evidence for Daclizumab HYP in Relapsing-Remitting MS

Data from patients with relapsing-remitting multiple sclerosis (MS) who received the humanized monoclonal antibody daclizumab high-yield process (HYP) “extend previous observations” on the agent’s rapid pharmacodynamic effects on CD56bright natural killer (NK) cells and regulatory T-cells (Tregs) at treatment initiation, providing additional evidence for an immunomodulatory effect.